Clinical Trial Results:
A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF MAPATUMUMAB ( [HGS1012], A
FULLY HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATION
WITH CARBOPLATIN AND PACLITAXEL AS FIRST LINE THERAPY IN
SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Summary
|
|
EudraCT number |
2007-005153-32 |
Trial protocol |
DE HU |
Global completion date |
29 Mar 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Jan 2019
|
First version publication date |
30 Jan 2019
|
Other versions |
|
Summary report(s) |
gsk-hgs1012-c1072-synopsis-redact |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.